Article citationsMore>>

Ruscitti, P., Cipriani, P., Cantarini, L., Liakouli, V., Vitale, A., Carubbi, F., et al. (2015) Efficacy of Inhibition of IL-1 in Patients with Rheumatoid Arthritis and Type 2 Diabetes Mellitus: Two Case Reports and Review of the Literature. Journal of Medical Case Reports, 9, Article No. 123.
https://doi.org/10.1186/s13256-015-0603-y

has been cited by the following article:

• TITLE: Current Indications for IL-1 Inhibition in Rheumatology

  AUTHORS: Soukaina Zaher, Kawtar Nassar, Ahlam Ajerouassi, Wafae Rachidi, Saadia Janani

  KEYWORDS: Interleukin 1, Anti-Interleukin 1, Auto-Inflammatory Disease, Anakinra, Canakinumab, Rilonacept

  JOURNAL NAME: Open Journal of Rheumatology and Autoimmune Diseases, Vol.15 No.4, November 28, 2025

  ABSTRACT: Interleukin-1 pro-inflammatory cytokines orchestrate local and systemic inflammatory responses in several diseases. Three therapeutic agents for reducing the activities of IL-1 are currently available. Conditions effectively treated with IL-1 blocking agents range from classical rheumatic diseases to autoinflammatory syndromes. In addition, IL-1 antagonism is also effective against other very common diseases, namely cardiovascular disease and type 2 diabetes, which are also co-morbidities, frequently found in patients with rheumatic diseases. Therefore, inhibition of IL-1 may provide clinical benefits beyond the efficacy of osteoarticular manifestations. The purpose of this article is to review the indications for anti-interleukins 1 in rheumatology.